Abstract
Recent epidemiological developments demonstrated that gene segments of swine influenza A viruses can account for antigenic changes as well as reduced drug susceptibility of pandemic influenza A viruses. This raises questions about the efficacy of preventive measures against swine influenza A viruses. Here, the protective effect of vaccination was compared with that of prophylactic Tamiflu® treatment against two Eurasian swine influenza A viruses. 11-week-old pigs were infected by aerosol nebulisation with high doses of influenza virus A/swine/Potsdam/15/1981 (H1N1/1981, heterologous challenge to H1N1 vaccine strain) and A/swine/Bakum/1832/2000 (H1N2/2000, homologous challenge to H1N2 vaccine strain) in two independent trials. In each trial (i) 10 pigs were vaccinated twice with a trivalent vaccine (RESPIPORC® FLU3; 28 and 7 days before infection), (ii) another 10 pigs received 150 mg/day of Tamiflu® for 5 days starting 12 h before infection, and (iii) 12 virus-infected pigs were left unvaccinated and untreated and served as controls. Both viruses replicated efficiently in porcine respiratory organs causing influenza with fever, dyspnoea, and pneumonia. Tamiflu® treatment as well as vaccination prevented clinical signs and significantly reduced virus shedding. Whereas after homologous challenge with H1N2/2000 no infectious virus in lung and hardly any lung inflammation were detected, the virus titre was not and the lung pathology was only partially reduced in H1N1/1981, heterologous challenged pigs. Tamiflu® application did not affect these study parameters.In conclusion, all tested preventive measures provided protection against disease. Vaccination additionally prevented virus replication and histopathological changes in the lung of homologous challenged pigs.
Highlights
Vaccines and antiviral drugs are essential means for control of influenza [1]
Since H3N2 viruses circulating in humans are resistant to this drug class [17,18] a situation of nearly 100% prevalence of ion channel inhibitor resistance was caused worldwide and neuraminidase inhibitors (NAI) like TamifluH and RelenzaH are the only drugs considered for additional prophylactic use at the moment
Because the vaccine strain H1N1/2003 was isolated after 22 years of evolution of these viruses in pigs and vaccinated pigs do not cross-react in HI with H1N1/1981, challenge with H1N1/ 1981 allows studying the efficacy of vaccination against heterologous challenge with a not cross-reactive strain of the same influenza A virus subtype in comparison to the prophylactic effect of TamifluH
Summary
Vaccines and antiviral drugs are essential means for control of influenza [1]. The fast spread and frequent mutation rate of influenza viruses contribute to high incidence and variability of these viruses in seasonal, epidemic, and pandemic influenza [2,3]. As shown by the emergence of pandemic influenza A H1N1(2009) virus (pH1N1/ 2009) such reassorted viruses can represent a worldwide threat [10,11,12]. PH1N1/2009 became resistant to M2 channel inhibitors [13,14] by accepting the matrix protein-coding gene of European swine influenza A viruses which confers the drug resistance [15,16]. Since H3N2 viruses circulating in humans are resistant to this drug class [17,18] a situation of nearly 100% prevalence of ion channel inhibitor resistance was caused worldwide and neuraminidase inhibitors (NAI) like TamifluH and RelenzaH are the only drugs considered for additional prophylactic use at the moment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
